By webmin on
Phone
N/A
Email
earlyaccess@emdserono.com
ClinicalTrials.gov URL
https://clinicaltrials.gov/ct2/results?cond=&term=&spons=serono&cntry=&state=&city=&dist=&Search=Search&recrs=a&recrs=b&recrs=d
Acknowledgement
5 business days
EA Page
http://www.emdserono.com/en/research/early_access_experimental_medicine/early_a…
COVID-19 Information

As part of the global effort to investigate potential therapeutics for COVID-19 and our support of independent research, Merck KGaA, (EMD Serono's parent company) recently donated a supply of interferon beta-1a (Rebif®) to the French Institut National de la Santé et de la Recherche Médicale (INSERM) following a request for use in a clinical trial.

The trial is sponsored by INSERM and its launch has been announced by the French Health authorities on March 11, 2020. To date, Merck KGaA, Darmstadt, Germany’s interferon beta-1a is not approved by any regulatory authority for the treatment of COVID-19 or for use as an antiviral agent.

See: Adverse Events Related to Treatments Used Against Coronavirus Disease 2019

 

Company Type
Late Onset Intervention